Immune checkpoints are a collection of molecular networks that regulate the immune system. Therapeutic approaches that inhibit the checkpoint molecules have demonstrated considerable benefit for cancer therapy. The use of these immuno-oncology drugs represent a new era in clinical management of patients with cancer and differ considerably from surgery, chemotherapy, radiotherapy and targeted therapy-based treatment methods for cancer. This symposium will provide an update on the latest developments in immuno-oncology as well as discuss best practices for managing patients receiving treatment with immuno-oncology drugs. Attendees will have the opportunity to share their experiences, participate in the discussion and ask questions to our experts. Join us at COSA 2014 to learn about the latest developments and considerations on the safety and efficacy of immune-oncology therapies.
This dinner symposium is free for conference delegates, but it’s important to register because Bristol-Myers Squibb will be providing dinner! You can register by selecting this dinner symposium in the 'add-ons' section of the registration portal.